Indivior PLC (LON:INDV)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | n/a |
| Revenue (ttm) | 905.57M |
| Net Income (ttm) | -47.99M |
| Shares Out | n/a |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | 12.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,726,430 |
| Average Volume | 704,436 |
| Open | 1,248.00 |
| Previous Close | 1,219.00 |
| Day's Range | 1,230.00 - 1,264.00 |
| 52-Week Range | 554.50 - 1,264.00 |
| Beta | 0.26 |
| RSI | 71.54 |
| Earnings Date | Jul 31, 2025 |
About Theseus Pharmaceuticals
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Indivior's Strategic Turnaround Gains Traction Post-Q2 2025
Indivior outlines $1.03B–$1.08B 2025 revenue guidance and cost structure overhaul through action agenda
Indivior PLC 2025 Q2 - Results - Earnings Call Presentation
Indivior PLC (INDV) Q2 2025 Earnings Call Transcript
Indivior (INDV) Q2 EPS Jumps 104%
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-Year Indivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call S...
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; ...
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, United Kingdom and RICHMOND, Va. , July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing o...
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine...
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
RICHMOND, Va. , July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m.
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
RICHMOND, Va. , July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 20...
Indivior to join Russell 2000 Index
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part ...
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va. , June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, eff...
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy ...
Drugmaker Invidior to abandon London listing amid exodus of companies
Firm behind opioid addiction treatment drugs quits London Stock Exchange after moving primary to US last year Business live – latest updates The drugmaker Indivior has become the latest company to aba...
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq
Drug maker Indivior to abandon London stock market for the US
Indivior’s exit comes after the company moved its primary listing to the US’s Nasdaq index last year.
Drug maker Indivior joins the flight from London share listings
Pharmaceuticals company said most of its product sales and shareholders are US based
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align...
UK Stock Market News: Vodafone, Indivior, ME Group
Vodafone announces completion of Three deal, Indivior to cancel London listing, focus on NY, laundry performance cycles up at ME Group
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("O...
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patri...
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New Yor...